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Background
The high level of genetic diversity of HIV-1 poses a major
challenge for global vaccine development. Vaccines based
on centralized sequences would minimize genetic dis-
tances to multiple clades and potentially maximize cross-
reactivity. Whether reactivity of these centralized peptide
reagents differs in mono- and multi-clade epidemic is
unknown.
Methods
In this study, full-length gag and nef gene sequences (from
Cameroon, 50 and 54, respectively and South Africa,
23 and 19, respectively) were characterized. HIV-specific
T-cell responses to group M consensus Gag and Nef pep-
tide reagents were characterized at the peptide level using
the IFN-g ELISpot assay.
Results
Viruses from Cameron exhibited a large degree of genetic
diversity; all subtypes were present excluding subtype C,
with CRF02_AG being dominating (49%). Contrary,
sequenced viruses from South Africa were all pure subtype
C viruses. Despite the greater diversity of viral clades in
the Cameroonian cohort, the genetic distances to the con-
sensus M reagents was similar for both cohorts (11% and
15% for Gag and Nef, respectively). Whilst the magnitude
and breadth of responses to Con M Gag and Nef did not
differ significantly between the two cohorts, there was a
greater frequency of responders in the Cameroonian
cohort compared to South Africans (95% versus 82%,
respectively). For the Cameroonian cohort, 75/182 (41%)
of the consensus M peptides were targeted, while for the
South African cohort 66/182 (36%) of the peptides were
targeted, with the majority being recognized in only 1-2
participants (69% and 76%, respectively). Patterns of
immunodominance and targeting, however, differed dra-
matically between the two cohorts, with only 36% and 39%
of Gag and Nef peptides commonly recognized between
the two cohorts.
Conclusion
Although similarities in total magnitude and breadth may
be observed between different epidemics, patterns of
immunodominance of centralized immunogens may be
different which may have implications for vaccine
development.
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